Abstract
The novel atypical antipsychotic ziprasidone has a pharmacologic profile notable for potent agonism of serotonin (5-HT)1A receptors, antagonism at 5-HT1D receptors, and reuptake inhibition of norepinephrine. 5-HT1A receptor agonism, in particular, suggests anxiolytic activity, and ziprasidone has shown preliminary efficacy in treating the symptoms of anxiety associated with psychotic disorders. In this study, the anxiolytic efficacy of ziprasidone was evaluated in nonpsychotic subjects who were anxious before undergoing minor dental surgery. We compared a single oral dose of 20 mg ziprasidone (N = 30) with that of 10 mg diazepam (N = 30) and placebo (N = 30) in a randomized, parallel-group, double-blind study. The peak anxiolytic effect of ziprasidone compared with that of placebo was similar to that of diazepam but had a later onset. At 3 hours postdose, the anxiolytic effect of ziprasidone was significantly greater than that of placebo (p < 0.05) and somewhat greater than that of diazepam. Diazepam showed a significantly greater anxiolytic effect than placebo at 1 hour (p < 0.05) but not at 3 hours. The sedative effect of ziprasidone was never greater than that of placebo, whereas that of diazepam was significantly greater th...Continue Reading
References
Jan 1, 1978·Clinical Pharmacokinetics·M MandelliS Garattini
Apr 1, 1992·Trends in Pharmacological Sciences·P R HartigR L Weinshank
Nov 1, 1991·Acta Psychiatrica Scandinavica·O Lingjaerde
Nov 1, 1991·Psychological Medicine·R M Norman, A K Malla
Jun 9, 1995·Journal of Chromatography. B, Biomedical Applications·J S JaniszewskiR O Cole
Dec 1, 1993·The Japanese Journal of Psychiatry and Neurology·Y Henmi
Mar 1, 1996·Psychopharmacology·A SchotteJ E Leysen
May 2, 1998·The Australian and New Zealand Journal of Psychiatry·S J Cosoff, R J Hafner
May 26, 1998·European Journal of Pharmacology·M E BeneytezJ Manzanares
Aug 5, 1998·International Clinical Psychopharmacology·J F Deakin
Dec 22, 1998·Psychopharmacology·P KeckM R Morrissey
Apr 8, 1999·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·D G DanielM Lakshminarayanan
Citations
Oct 14, 2006·Rheumatology International·Elena P CalandreFernando Rico-Villademoros
Jul 30, 2005·Diabetes, Obesity & Metabolism·A J GoudieJ C G Halford
Nov 6, 2007·Expert Opinion on Emerging Drugs·Nirvana S Pillay, Dan J Stein
Feb 25, 2011·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Nienke C C VulinkDamiaan Denys
Dec 22, 2004·Progress in Neuro-psychopharmacology & Biological Psychiatry·Fernando Rico-VillademorosElena Pita Calandre
Dec 9, 2014·Expert Opinion on Drug Metabolism & Toxicology·Roberto MandrioliLaura Mercolini
Feb 5, 2013·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Julia DiemerPeter Zwanzger
Feb 16, 2011·The International Journal of Neuropsychopharmacology·Luis H RipollLarry J Siever
Jun 28, 2005·International Journal of Psychiatry in Medicine·Steven A ColeAngela Smith
Oct 15, 2009·Journal of Psychopharmacology·Christopher GonanoBurkhard Gustorff
Jul 19, 2008·Journal of Psychopharmacology·D NuttF Baldinetti
Dec 15, 2010·The Cochrane Database of Systematic Reviews·Anna M DeppingStefan Leucht
Jul 16, 2010·Journal of Clinical Psychopharmacology·Michael KellnerKlaus Wiedemann
Mar 4, 2005·CNS Spectrums·Daniel L Crane